XARELTO®: Dosing for venous thromboembolism (VTE) prophylaxis in acutely ill medical patients

XARELTO®: Once-daily oral dose for vte risk reduction in acutely ill medical patients both inpatient and outpatient

10 mg

Once daily, in hospital and after hospital discharge, for a total recommended duration of 31 to 39 days with or without food in patients with a CrCl 15 mL/min

Renal Dose Considerations*

  • Avoid using XARELTO® in patients with CrCl <15 mL/min

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*Calculate CrCl based on actual weight.

Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).

The decision regarding initiation setting should be based on the prescriber's clinical judgment.

CrCl = creatinine clearance; VTE= venous thrombotic embolism.

Need Help?